2012
DOI: 10.1186/cc11707
|View full text |Cite
|
Sign up to set email alerts
|

Erythropoietin enhances the effects of transplanted mesenchymal stem cells in an experimental model of endotoxemia

Abstract: Background: Most clinical trials of sepsis treatment modalities fail at their primary objective of establishing superiority over placebo when added to background standard of care. While there is no definitive explanation for the high failure rate, it might be stated that our attempts to insert a new therapeutic agent into standard of care encounters severe problems with definition of exactly what stage is ongoing, and what are the criteria for progression or resolution from that time point onwards. Clearly the… Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles